checkAd
    Startseite > Aktien > AN2 Therapeutics > Nachrichten
    AN2 Therapeutics Aktie
    2,4200
     
    USD
    -2,02 %
    -0,0500 USD
    Letzter Kurs 02:00:00 Nasdaq
    2,4200
     
    USD
    100 STK
    Geldkurs 10.05.24
    2,4400
     
    USD
    600 STK
    Briefkurs 10.05.24
    ISIN: US0373261058 · WKN: A3DKYC · SYM: ANTX · USA

    Neueste Nachrichten

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
    28.03.24 · Business Wire (engl.) · AN2 Therapeutics
    AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
    12.02.24 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
    30.01.24 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
    09.11.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics to Present at Upcoming Investor Conferences
    06.11.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
    18.10.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
    11.10.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
    26.09.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
    13.09.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
    16.08.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
    10.08.23 · Business Wire (engl.) · AN2 Therapeutics
    AN2 Therapeutics to Present at Jefferies Healthcare Conference
    25.05.23 · Business Wire (engl.) · AN2 Therapeutics